放射治疗后食道状细胞癌的辅助免疫疗法:回顾性多中心生存分析
Weiwei Zeng1,2, Jianlin Long3, Benxu Tan1,2
1Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
概括
辅助免疫疗法显著改善了食道状细胞癌 (ESCC) 患者的整体存活率 (OS) 和无进展存活率 (PFS). 这项研究证实了免疫治疗在未切割的ESCC放射后疗法的益处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 消化道癌研究 消化道癌研究
背景情况:
- 免疫疗法在各种食道癌症情况下提供了生存益处.
- 免疫疗法在食道状细胞癌 (ESCC) 中的辅助作用需要进一步研究.
- 这项研究解决了围绕辅助免疫治疗在ESCC中的疗效的不确定性.
研究的目的:
- 评估辅助免疫治疗对未切除ESCC患者的生存结果的影响.
- 确定辅助免疫疗法是否提高ESCC患者放射治疗后的整体存活率 (OS) 和无进展存活率 (PFS).
主要方法:
- 在接受放射治疗的未切除ESCC患者中进行了多中心倾向-得分匹配分析.
- 卡普兰-梅尔分析和日志等级测试被用来生成和比较生存曲线.
- 统计分析使用了单变量和多变量考克斯回归模型.
主要成果:
- 辅助免疫疗法与非免疫疗法组中42个月的中位数生存寿命相关,而非免疫疗法组的平均寿命为22个月 (HR,0.55).
- 辅助免疫治疗的PFS中位数为26个月,而没有辅助免疫治疗的PFS中位数为17个月 (HR,0.58).
- 倾向性得分匹配证实辅助免疫疗法显著改善了PFS (HR,0.49) 和OS (HR,0.50).
结论:
- 放射治疗后的辅助免疫疗法在未切除ESCC的患者中显著改善了OS和PFS.
- 这些发现支持在ESCC的管理中使用辅助免疫疗法.
- 进一步的研究可能会在多变量分析中探索预后因素.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
05:57ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
Published on: February 10, 2017
8.8K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:21Cancer Survival Analysis
629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629